menu
    • menu
    [{"orgOrder":0,"company":"Innovaderm","sponsor":"Aralez Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase II\/ Phase III","graph3":"Innovaderm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Innovaderm \/ Aralez Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Innovaderm \/ Aralez Pharmaceuticals"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ OSI PHARMS","highestDevelopmentStatusID":"11","companyTruncated":"The University of Pittsburgh School of Medicine \/ OSI PHARMS"},{"orgOrder":0,"company":"Amylynne Frankel","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Acitretin","moa":"Retinoid receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amylynne Frankel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amylynne Frankel \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Amylynne Frankel \/ GSK"}]

    Find Clinical Drug Pipeline Developments & Deals for Acitretin

    Menu

    Acitretin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Innovaderm

                            Canada arrow
                            OTS 2025
                            Not Confirmed

                            Innovaderm

                            Canada arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Aralez Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis

                            Details : Acitretin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dermatitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2012

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Aralez Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            The University of Pittsburgh School of Medicine

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)

                            Details : Acitretin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Exanthema.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2011

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Astellas Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amylynne Frankel

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Amylynne Frankel

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

                            Details : Acitretin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 26, 2010

                            Lead Product(s) : Acitretin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth